Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    Contact Supplier

    Menu

    Aramchol meglumine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 4,133Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    galmed identifies biomarker for aramchol, expanding beyond NASH
    galmed identifies biomarker for aramchol, expanding beyond NASH

    27 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-identifies-proprietary-biomarker-signature-for-aramchol-unlocking-multi-billion-dollar-expansion-potential-beyond-nash-302465691.html

    PR NEWSWIRE
    27 May 2025
    Share Share
    Galmed Reports Anti-Fibrotic Effects of Aramchol in PSC Models
    Galmed Reports Anti-Fibrotic Effects of Aramchol in PSC Models

    13 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-reports-significant-anti-fibrotic-effects-of-aramchol-in-psc-models-302453710.html

    PR NEWSWIRE
    13 May 2025
    Share Share
    Galmed: Aramchol Boosts Bayer's Regorafenib in GI Cancer Models
    Galmed: Aramchol Boosts Bayer's Regorafenib in GI Cancer Models

    06 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-announces-first-time-results-in-oncology-studies-aramchol-significantly-enhances-bayers-regorafenib-effect-in-gi-cancer-models-302447161.html

    PR NEWSWIRE
    06 May 2025
    Share Share
    Galmed Pharmaceuticals & VCU Collab on Drug Resistance GI Cancer
    Galmed Pharmaceuticals & VCU Collab on Drug Resistance GI Cancer

    17 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-launches-vcu-collaboration-to-tackle-drug-resistance-in-gi-cancers-302431484.html

    PR NEWSWIRE
    17 Apr 2025
    Share Share
    Galmed Reveals New Blood Markers for Aramchol, Advanced SCD1 Inhi
    Galmed Reveals New Blood Markers for Aramchol, Advanced SCD1 Inhi

    15 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-unveils-novel-pharmacodynamic-blood-markers-for-aramchol-the-most-clinically-advanced-scd1-inhibitor-302428834.html

    PR NEWSWIRE
    15 Apr 2025
    Share Share
    Galmed Pharmaceuticals Extends Aramchol Patent Protection to 2039
    Galmed Pharmaceuticals Extends Aramchol Patent Protection to 2039

    20 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-secures-new-patent-grant-extending-aramchols-patent-protection-to-2039-strengthening-leadership-in-nashmash-combination-therapy-302407043.html

    PR NEWSWIRE
    20 Mar 2025
    Share Share